Insight Molecular Diagnostics Inc Dossier
Qualitative Analysis
Business overview
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX), formerly known as Oncocyte Corporation, is a Nashville, Tennessee-based precision diagnostics technology company. The company focuses on democratizing access to novel molecular diagnostic testing to improve patient outcomes, with its initial strategic focus on transplant rejection monitoring. Its flagship technology platform, commercialized under the GraftAssure brand, quantifies donor-derived cell-free DNA (dd-cfDNA), an established molecular biomarker for transplant rejection. In addition to its transplant diagnostics portfolio, the company offers oncology-focused tools including DetermaIO, a gene expression test assessing the tumor microenvironment to predict immunotherapy response, and DetermaCNI, a blood-based cancer treatment monitoring tool.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting from a centralized laboratory services model to a decentralized, kitted assay model under the GraftAssure brand. This strategy aims to democratize access by enabling local transplant laboratories to run donor-derived cell-free DNA (dd-cfDNA) testing in-house, reducing turnaround times and operational costs.
Expected impact: Enables the company to capture market share in the estimated $2 billion-plus addressable market for transplant rejection testing and generate high-margin, recurring product revenue.
Expanding the GALACTIC (GraftAssure Lowering Allograft rejeCTIon by Combination) registry study to drive clinical adoption and build real-world scientific evidence. The study focuses on establishing absolute quantification of dd-cfDNA as a critical metric for transplant monitoring.
Expected impact: Builds clinical credibility, supports reimbursement coverage, and establishes a pipeline of transplant centers ready to transition to commercial kitted assays upon regulatory approval.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to expand the company's molecular diagnostics portfolio into immuno-oncology and therapeutic stratification, adding the IM Score test and a CAP/CLIA-certified laboratory in Nashville, Tennessee.
Financial impact: Provided the core CLIA-certified laboratory infrastructure in Nashville that now supports the company's transplant and oncology testing services.
Strategic Partnerships
Bio-Rad is a major strategic partner and equity investor. The partnership focuses on developing and commercializing kitted transplant products (GraftAssure) designed to run on Bio-Rad's digital PCR (ddPCR) instruments and reagents. Bio-Rad holds a 90-day right of first negotiation for commercialization post-FDA authorization.
Terms: Bio-Rad participated as an investor in the company's $26 million registered direct offering in February 2026 (marking its fourth equity investment) and has provided in-kind scientific and development support.